Cozad Asset Management Inc. Has $857,000 Stake in Cencora, Inc. (NYSE:COR)

Cozad Asset Management Inc. boosted its stake in Cencora, Inc. (NYSE:COR - Free Report) by 64.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,815 shares of the company's stock after buying an additional 1,490 shares during the quarter. Cozad Asset Management Inc.'s holdings in Cencora were worth $857,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Swedbank AB increased its holdings in Cencora by 2.3% in the third quarter. Swedbank AB now owns 1,394,449 shares of the company's stock worth $313,863,000 after buying an additional 31,104 shares during the last quarter. United Bank increased its stake in shares of Cencora by 4.2% during the 3rd quarter. United Bank now owns 5,601 shares of the company's stock worth $1,261,000 after purchasing an additional 225 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in shares of Cencora by 2.0% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 5,850 shares of the company's stock worth $1,317,000 after purchasing an additional 115 shares during the last quarter. Natixis Advisors LLC raised its holdings in shares of Cencora by 3.9% during the 3rd quarter. Natixis Advisors LLC now owns 139,028 shares of the company's stock valued at $31,292,000 after purchasing an additional 5,198 shares in the last quarter. Finally, Mutual of America Capital Management LLC lifted its stake in shares of Cencora by 2.9% in the 3rd quarter. Mutual of America Capital Management LLC now owns 21,528 shares of the company's stock valued at $4,846,000 after purchasing an additional 605 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Remove Ads

Insider Activity

In related news, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,970 shares of company stock worth $2,998,670. Corporate insiders own 10.80% of the company's stock.

Cencora Stock Performance

Shares of NYSE COR traded down $0.93 during mid-day trading on Friday, hitting $266.91. The company had a trading volume of 6,526,576 shares, compared to its average volume of 1,631,284. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $271.08. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm has a market cap of $51.76 billion, a P/E ratio of 37.97, a PEG ratio of 1.31 and a beta of 0.51. The business's 50-day simple moving average is $250.01 and its 200-day simple moving average is $239.87.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is 31.29%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on COR shares. Wells Fargo & Company increased their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. JPMorgan Chase & Co. raised their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Evercore ISI increased their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Mizuho began coverage on shares of Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective for the company. Finally, StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and an average target price of $280.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.